Brian Gilger

Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA.

Tisbury Pharmaceuticals Ltd. develops and markets groundbreaking therapy to treat primary open angle glaucoma. It focused on the discovery, development, and commercialization of groundbreaking therapy to treat primary open angle glaucoma. The company was founded by Andrew L. Salzman and is headquartered in Beverly, MA.

Nacuity Pharmaceuticals, Inc. develops and markets pharmaceutical products. The company is headquartered in Fort Worth, TX.

Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021.

Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation.

SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France.

The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD.

Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC.

Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC.

The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC.

GeneTech, Inc. engages in fetal deoxyribonucleic acid (DNA) testing and clinical services. The company was founded on October 5, 2010 and is headquartered in Tokyo, Japan.